secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001104659-23-033367
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova full-year net loss $19.0M; cash $38.8M into Q1 2024
------------------------------------------------------------

- Net loss $19.0M ($0.91 loss per share) vs $16.2M ($0.96 loss per share) in 2021 on higher shares outstanding.
- Cash and equivalents $38.8M at Dec 31, 2022, down from $55.1M; cash runway into Q1 2024.
- R&D expenses rose to $11.4M from $7.3M, driven by narazaciclib development and manufacturing.
- Narazaciclib Phase 1 advancing to 240 mg continuous daily cohort; LGEEC trial opening Q1 2023, data Q4 2023.
- Two complete responses in RDEB-associated SCC with rigosertib; plan to discuss regulatory path with agencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/0001104659-23-033367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/tm239793d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-033367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer